Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
63.5 PLN | +1.44% | +1.44% | +8.55% |
Mar. 18 | Selvita S.A. Launches Biologic Drug Discovery and Development Services | CI |
Nov. 15 | Selvita S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Sales 2023 * | 359M 89.76M | Sales 2024 * | 424M 106M | Capitalization | 1.15B 287M |
---|---|---|---|---|---|
Net income 2023 * | 13M 3.25M | Net income 2024 * | 31M 7.75M | EV / Sales 2023 * | 3.66 x |
Net Debt 2023 * | 167M 41.66M | Net Debt 2024 * | 205M 51.2M | EV / Sales 2024 * | 3.19 x |
P/E ratio 2023 * |
110
x | P/E ratio 2024 * |
35.2
x | Employees | 404 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 78.23% |
1 day | +1.44% | ||
1 week | +1.44% | ||
Current month | +8.18% | ||
1 month | +7.81% | ||
3 months | +5.83% | ||
6 months | +6.37% | ||
Current year | +8.55% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 07-08-31 | |
Dariusz Kurdas
DFI | Director of Finance/CFO | - | 19-07-31 |
Miroslawa Zydron
COO | Chief Operating Officer | - | 09-01-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jacek Osowski
BRD | Director/Board Member | 47 | 19-09-18 |
Director/Board Member | - | 19-09-18 | |
Director/Board Member | 72 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 63.5 | +1.44% | 11 179 |
24-03-27 | 62.6 | +2.29% | 3,951 |
24-03-26 | 61.2 | -0.97% | 2,352 |
24-03-25 | 61.8 | -0.96% | 1,201 |
24-03-22 | 62.4 | -0.32% | 1,108 |
Delayed Quote Warsaw S.E., March 28, 2024 at 05:32 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+8.55% | 288M | |
+9.16% | 45.97B | |
+54.03% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |